Dublin, Feb. 13, 2024 (GLOBE NEWSWIRE) -- The "Biosimilar Interleukins Global Market Report 2024" has been added to ResearchAndMarkets.com's offering.
The latest comprehensive research on the global biosimilar interleukins market unveils a surge in market size, forecasted to accelerate from $3.9 billion in 2023 to an astounding $20.79 billion by 2028.
This significant growth trajectory, pegged at a compound annual growth rate (CAGR) of 40.0%, reflects an increased demand for biosimilar interleukins across diverse healthcare settings. The market's robust expansion is attributed to a combination of factors, including an uptick in the prevalence of autoimmune diseases, an aging population, and the overarching necessity for cost-effective therapeutic alternatives.
Evolving treatment protocols and the rising incidence of autoimmune conditions, such as rheumatoid arthritis and psoriasis, have underpinned the heightened usage of biosimilar interleukins. Such market dynamics have prompted an array of pharmaceutical entities to innovate and diversify their portfolios.
In alignment with market forces, the biosimilar interleukins market is witnessing an influx of strategic corporate maneuvers. Illustrative of these trends, Equillium's acquisition of Bioniz Therapeutics magnifies its developmental pipeline, showcasing the market's competitive and innovative landscape.
The global market's largest share belonged to North America in 2023; nonetheless, other regions are rapidly gaining ground. The research underscores the global nature of the market, with a detailed analysis of key regions that include the Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East, and Africa.
Key Market Segments and Distribution Channels
The thorough market analysis delineates several crucial segments within the biosimilar interleukins sector. Interleukins such as IL-17, IL-23, IL-1, IL-5, and IL-6 are under the spotlight, given their therapeutic significance in managing conditions such as psoriasis, rheumatoid arthritis, and asthma.
- The research elucidates these drugs' pathways from manufacture to market, spanning hospital pharmacies, online pharmacies, retail pharmacies, and clinics.
- Insights into the market's trends, challenges, and opportunities equip relevant stakeholders with the necessary foresight to navigate this terrain.
The biosimilar interleukins market research offers an indispensable resource for those looking to harness the potential within this burgeoning field. Moreover, it provides a strategic outlook, presenting an in-depth market evaluation amidst a rapidly shifting healthcare landscape.
As the pharmaceutical industry pivots towards more personalized, effective, and accessible treatment options, biosimilar interleukins stand at the forefront of this evolution.
Key Markets Covered:
- By Type: IL-17; IL-23; IL-1; IL-5; IL-6
- By Application: Psoriasis; Psoriatic Arthritis; Rheumatoid Arthritis; Asthma; Inflammatory Bowel Disease (IBD); Other Applications
- By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies; Clinics; Research Institutes
Companies Profiled:
- Mabpharm Limitied
- Gedeon Richter plc
- Bio-Thera Solutions Ltd.
- Sorrento Therapeutics
- Sunshine Guojian Pharmaceutical
- Stada Arzneimittel AG
- Teva Pharmaceutical Industries
- 3SBio Inc.
- Shanghai Fosun Pharmaceuticals
- Biogen Inc.
- Novartis AG
- Pfizer Inc.
- AbbVie Inc.
- Amgen Inc.
- F. Hoffmann-La Roche AG
- Sanofi SA
- Merck & Co. Inc.
- GlaxoSmithKline plc
- Eli Lilly and Company
- AstraZeneca plc
- Bristol-Myers Squibb Company
- Qilu Pharmaceutical
- Tonghua Dongbao
- PROBIOMED S.A. de C.V.
- Biosidus S.A.
- LG Life Sciences
- Mylan N.V.
For more information about this report visit https://www.researchandmarkets.com/r/puuyzs
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
